Drug intelligence / Profile preview

Axonorm NP

Development stage
Unknown
Lead developer
Gonan Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Axonorm NP is a fixed-dose combination pharmaceutical product marketed by Gonan Pharma for the management of neuropathic pain. It contains three active ingredients: pregabalin, nortriptyline, and methylcobalamin. Pregabalin is an alpha-2-delta ligand that binds to voltage-gated calcium channels in the central nervous system, thereby reducing the release of several excitatory neurotransmitters and modulating pain signaling. Nortriptyline is a tricyclic antidepressant that inhibits the reuptake of serotonin and noradrenaline, enhancing the descending inhibitory pain pathways. Methylcobalamin, a form of Vitamin B12, acts as a cofactor for methionine synthase and is essential for the production of myelin, aiding in nerve regeneration and the repair of damaged nerve cells. The product is formulated as a sustained-release (SR) tablet for oral administration and is typically indicated for chronic pain resulting from diabetic neuropathy, postherpetic neuralgia (shingles), or spinal cord injury.

Brand names
Axonorm NP
02

Targets

MTR (Methionine synthase)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on Axonorm NP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axonorm NP.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call